Home | Structured Search | Drug Resource
Find: within
Acute Viral Conjunctivitis > Diagnosis Author: Stephen Orlin, MD
Module updated - 2008-04-08
Author information and module status
Prevention
Screening
Diagnosis
Consultation for Diagnosis
Hospitalization
Non-drug Therapy
Drug Therapy
Patient Education
Consultation for Management
Follow-up

Tables
Figures
References
Glossary
What's New
Patient Information
Additional Resources
Tools

Rationale:

  • Snellen acuity can be decreased by punctate keratitis and discharge and debris in tear film.
  • Acute viral infection tends to cause hyperemia, follicular response, and watery discharge.
  • Preauricular lymphadenopathy is prominent in acute adenoviral conjunctivitis but may also be present in picornaviral conjunctivitis.
  • Acute viral infection can cause marked exudative response, which can result in pseudomembranes in upper or lower fornix.
  • Bulbar conjunctiva may show petechial or large subconjunctival hemorrhages.
  • Corneal infiltrates (subepithelial infiltrates) may develop after the acute phase of the adenoviral disease subsides (day 7 to 10) but are rarely seen in picornaviral conjunctivitis.
  • Acute epithelial infiltrates and punctate keratitis in cornea stain green with fluorescein dye.

Evidence:

  • Physical exam features associated with viral conjunctivitis are reviewed in an article (1) and in a book chapter about diseases of the outer eye (3).
  • Epidemiologic and clinically based studies clearly document clinical features of epidemic keratoconjunctivitis (10; 11).
  • Lymphadenopathy is found in approximately 50% of patients (12).
  • Acute viral disease is usually bilateral but may be unilateral in up to 20% of cases (1; 13).
  • The development of corneal infiltrates is an inflammatory repsonse that may occur in 35% to 50% of patients with epidemic keratoconjunctivitis (12; 13; 14; 15).
  • Adenoviral positive cultures may be found in 5% to 10% of patients at 14 days (16).

Comments:

  • Studies suggest that it is often difficult to differentiate viral from bacterial or allergic disease by the clinical exam. Clinical accuracy of about 40% to 70% compared to laboratory confirmation has been shown (6; 7; 17; 18; 9).

FAQs
Robert Sambursky, MD, editorial consultant, Chief Medical Officer for Rapid Pathogen Screening, Inc.;served as consultant for Rapid Pathogen Screening, Inc.;received an honoraria for Rapid Pathogen Screening, Inc.;serves as consultant for Rapid Pathogen Screening, Inc; owns stock options in Rapid Pathogen Screening, Inc.;served as board member or director for Rapid Pathogen Screening, Inc.;received grants and has grants pending from Rapid Pathogen Screening, Inc.;and has received patents and has patents pending for Rapid Pathogen Screening, Inc. Stephen Orlin, MD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Steven E. Weinberger, MD, FACP, Acting Editor, PIER, has stock holdings in Glaxosmithkline and Abbott.


The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted (c) 2009 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.